Dihexa vs PE-22-28.
Quick Verdict
Dihexa is a neurotropic peptide primarily researched for synaptogenesis, memory enhancement, cognitive repair, angiotensin iv activity, while PE-22-28 is a nootropic peptide studied for antidepressant, neuroplasticity, trek-1 channel blockade, fast-acting mood elevation.
Side-by-Side Analysis
| Dimension | Dihexa | PE-22-28 |
|---|---|---|
| Category | Neurotropic Peptide | Nootropic Peptide |
| Mechanism | Angiotensin IV analog developed at Washington State University. | Synthetic hexapeptide fragment derived from the propeptide of sortilin, an endogenous regulator of the TREK-1 potassium channel. |
| Half-Life | ~2 days | ~1 hours |
| Route | Oral | SubQ |
| Typical Dose | 5–20 mcg | 500–1000 mcg |
| Frequency | Infrequent (2-3x per week due to long half-life) | Daily |
| Evidence Level | Preclinical | Preclinical |
| Indexed Studies | 2+ indexed | 2+ indexed |
| FDA Status | Research Only | Research Only |
| Lowest Price | — | — |
Mechanism of Action Comparison
How Dihexa Works
Dihexa Dihexa is a brain-penetrating peptide from Washington State University research that triggers new synapse formation at extremely low doses — it's been called millions of times more potent than BDNF for this effect in rodent models.
Angiotensin IV analog developed at Washington State University. Binds hepatocyte growth factor (HGF) and potentiates its binding to the c-Met receptor, triggering downstream synaptogenesis cascades in hippocampal neurons. Reported to be 7 orders of magnitude more potent than BDNF for synaptic formation in vitro. Crosses blood-brain barrier and is orally bioavailable. Produces dose-dependent improvements in spatial memory in rodent models of cognitive impairment.
How PE-22-28 Works
PE-22-28 PE-22-28 is a spadin-derived peptide that blocks the TREK-1 potassium channel — a key culprit in depression — producing fast-acting antidepressant effects in animal models without typical SSRI side effects.
Synthetic hexapeptide fragment derived from the propeptide of sortilin, an endogenous regulator of the TREK-1 potassium channel. PE-22-28 competitively inhibits TREK-1, a background leak channel whose overactivation is implicated in depression and anxiety. By blocking TREK-1, PE-22-28 increases neuronal excitability in serotonergic circuits and promotes BDNF expression, producing rapid antidepressant effects in rodent models comparable to fluoxetine.
Key Mechanistic Difference
Dihexa operates as a neurotropic peptide, while PE-22-28 functions as a nootropic peptide — these are fundamentally different pharmacological approaches. Dihexa has a significantly longer half-life (~2 days) compared to PE-22-28 (~1 hours), which impacts dosing frequency and sustained activity.
Research Evidence
Dihexa
2 studies- Dihexa promotes synaptogenesis and cognitive function in rodentsMcCoy et al. (Journal of Pharmacology & Experimental Therapeutics): Dihexa produces dose-dependent improvements in spati…Preclinical
- Angiotensin IV analogs and HGF/c-Met signaling in memoryWright et al.: Establishes the mechanistic basis for angiotensin IV analog activity at HGF and c-Met, demonstrating memo…Preclinical
PE-22-28
2 studies- Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug designMazella et al. (PLOS Biology): Identifies spadin as a natural TREK-1 blocker with rapid antidepressant activity in roden…Preclinical
- PE-22-28 antidepressant effects and neuroplasticityDjillani et al.: PE-22-28, an optimized spadin analog, demonstrates superior TREK-1 inhibition, enhanced antidepressant …Preclinical
Vendor Pricing
· Affiliate links · Prices verified 2026Dihexa
PE-22-28
Affiliate disclosure: PeptiDex may earn a commission from purchases via vendor links at no extra cost to you. See our methodology.
Frequently Asked Questions
Can I take Dihexa and PE-22-28 together?▼
No direct interaction data is available for this specific pair. They target different receptor systems, suggesting they could potentially be combined, but no published protocol validates this combination.
Which has more research evidence — Dihexa or PE-22-28?▼
Dihexa has 2 indexed studies (highest evidence: Preclinical). PE-22-28 has 2 indexed studies (highest evidence: Preclinical). Both have comparable research coverage.
Which is better for brain focus — Dihexa or PE-22-28?▼
Both are researched for brain focus. Dihexa addresses this via synaptogenesis, memory enhancement, cognitive repair, angiotensin iv activity. PE-22-28 approaches it through antidepressant, neuroplasticity, trek-1 channel blockade, fast-acting mood elevation. The optimal choice depends on your specific research protocol and which mechanism aligns with your objectives.
Related Comparisons
Deep Dive Profiles
Research Use Only — Not Medical Advice
This comparison is provided for educational and research purposes only. It does not constitute medical, prescribing, or treatment advice. Clinical data cited here is sourced from published peer-reviewed trials and FDA labels. Consult a qualified healthcare professional before making any decisions about medications or research compounds. PeptiDex is an informational resource and does not sell pharmaceutical products.